Abbott has obtained regulatory approval for its XIENCE Xpedition Everolimus Eluting Coronary Stent system,designed for improving coronary artery luminal diameter in patients with symptomatic heart disease due to de novo native coronary ...
Tags: Abbott, FDA, Drug Eluting System, XIENCE, symptomatic heart disease